Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk A/S
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from two different production processes in patients with severe haemophilia A Ensayo clínico que investiga la farmacocinética y seguridad de una dosis única de turoctocog alfa pegol procedente de dos procesos de producción distintos en pacientes con hemofilia A grave
To evaluate and compare the single-dose pharmacokinetic of turoctocog alfa pegol from the pivotal process with turoctocog alfa pegol from the commercial process, each given as intravenous administrati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy and safety of liraglutide in subjects with type 1 diabetes undergoing islet cell
The primary objective is to investigate if treatment with liraglutide can increase the proportion of subjects who are insulin-independent one year after islet cell transplantation, and required only o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients with Haemophilia A
• To evaluate safety of N8 in paediatric previously treated patients (PTPs) <12 years of age with haemophilia A
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial investigating the efficacy and safety of insulin degludec in children and adolescents with type 1 diabetes mellitus
To confirm the efficacy of insulin degludec administered once daily plus mealtime insulin aspart in controlling glycaemia with respect to change from baseline in HBA1c after 26 weeks of treatment. Thi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without oral antidiabetic drugs
To compare the effects of insulin degludec once daily and insulin glargine 300 units/mL once daily on hypoglycaemia in subjects with type 2 diabetes mellitus, inadequately treated with basal insulin ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy of blood sugar control with Victoza® (liraglutide) vs. oral antidiabetic drugs as add-on to metformin treatment in subjects with type 2 diabetes inadequately controlled on metformin treatment alone
To compare the efficacy in controlling glycaemia with Victoza® (liraglutide) as add-on to metformin vs. oral antidiabetic drugs (OADs) as add-on to metformin after up to 104 weeks of treatment in subj...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment
To compare the effect of once-daily dosing of 14 mg oral semaglutide versus placebo, both in combination with metformin and/or sulfonylurea, basal insulin alone or metformin in combination with basal ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus
To assess and compare the dose-response of five doses of once-daily semaglutide versus placebo in inducing and maintaining weight loss after 52 weeks in obese subjects without diabetes mellitus
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Inhaled pre-prandial human insulin with the AERx® iDMS versus s.c. insulin aspart in type 2 diabetes: A 104-week, open-label, multicentre, randomised trial followed by 12-week re-randomised extension to investigate safety and efficacy
To compare the effect of pre-prandial inhaled human insulin administered with AERx to subcutaneous injections of pre-prandial insulin aspart (both in combination with insulin detemir) on glycaemic con...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B
To evaluate the immunogenicity of NNC-0156-0000-0009.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant